/
Understanding HDFN
Save to my account
Sign up
Understanding HDFN
BB HDFN
Study
1
Question
What is hemolytic disease of the fetus and newborn (HDFN)?
Answer
HDFN is a condition where the red blood cells of a fetus are coated with IgG alloantibodies from the mother that are directed against antigens of paternal origin present on fetal cells. This leads to accelerated destruction of the fetal red blood cells, which can vary in severity.
2
Question
What are the key characteristics of HDFN?
Answer
Characteristics of HDFN include: 1. IgG alloantibody involvement from the mother. 2. Coating of fetal red blood cells with maternal antibodies. 3. Possible outcomes ranging from severe anemia to intrauterine death. 4. Diagnosis often requires serologic tests to detect the antibodies.
3
Question
What are the differences between ABO and Rh HDFN?
Answer
ABO HDFN occurs when there is an incompatibility between the blood types of the mother and fetus, typically with type O mothers and A or B infants. It usually presents milder symptoms and may occur in the first pregnancy. Rh HDFN occurs specifically due to Rh incompatibility, typically in Rh-negative mothers with Rh-positive infants, and is more severe, particularly in subsequent pregnancies.
4
Question
What is Rh immune globulin, and what is its function?
Answer
Rh immune globulin is a blood product administered to Rh-negative mothers during or after pregnancy to prevent Rh immunization. It functions by binding to Rh-positive RBCs, preventing the mother's immune system from producing antibodies against them.
5
Question
What are the indications for administering Rh immune globulin?
Answer
Indications for Rh immune globulin include: 1. Rh-negative mother carrying an Rh-positive fetus. 2. After delivery of an Rh-positive infant. 3. During pregnancy after any event that risks fetal-maternal hemorrhage, such as trauma or invasive procedures.
6
Question
What are the contraindications for administering Rh immune globulin?
Answer
Contraindications for Rh immune globulin include: 1. Rh-negative mother with a confirmed Rh-negative infant. 2. History of severe allergic reactions to Rh immune globulin. 3. Mothers with pre-existing anti-D antibodies.
7
Question
What tests are used to detect feto-maternal hemorrhage in HDFN?
Answer
Tests used to detect feto-maternal hemorrhage include: 1. Kleihauer-Betke test - detects fetal red blood cells in maternal circulation. 2. Quantitative tests to estimate the volume of fetal blood in maternal circulation.
8
Question
Why is HDFN more severe after succeeding pregnancies if not treated accordingly?
Answer
HDFN tends to be more severe in subsequent pregnancies because the mother's immune response becomes sensitized to fetal Rh-positive blood cells during the first pregnancy, leading to increased production of antibodies during subsequent pregnancies.
9
Question
What happens to IgG coated fetal cells in HDFN?
Answer
IgG coated fetal cells undergo accelerated destruction both before and after birth, leading to anemia, jaundice, and potentially severe complications such as hydrops fetalis or intrauterine death.
10
Question
What is HDFN and what causes it?
Answer
HDFN (Hemolytic Disease of the Fetus and Newborn) is the destruction of fetal and neonatal red blood cells (RBCs) due to antibodies produced by the mother that target fetal antigens inherited from the father.
11
Question
Which immunoglobulin is primarily involved in HDFN and why is it significant?
Answer
IgG is the main immunoglobulin involved in HDFN because it can cross the placenta, allowing maternal antibodies to attack fetal RBCs. In contrast, IgM and IgA do not cross the placenta.
12
Question
What are the three categories of maternal immunization related to HDFN?
Answer
The three categories of maternal immunization related to HDFN are: 1. Severe - primarily due to Anti-D, possibly with Anti-C or Anti-E; 2. Rare - related to antibodies against other antigens in the Rh system, such as Anti-c or Anti-K; 3. Mild - related to ABO incompatibility, such as Anti-A,B in a group O mother or isolated Anti-A or Anti-B.
13
Question
How does ABO HDFN differ from Rh HDFN?
Answer
ABO HDFN typically occurs during the first pregnancy, is less severe than Rh HDFN due to less RBC destruction, and presents with less developed fetal RBCs at birth, leading to less destruction by maternal antibodies.
14
Question
What are the common clinical presentations of infants with ABO HDFN?
Answer
Infants may present with mild anemia and typically experience hyperbilirubinemia and jaundice within 12 to 48 hours after birth.
15
Question
What is the purpose of conducting a Rosette Test?
Answer
The Rosette Test is used to detect fetal-maternal hemorrhage (FMH) which may indicate the need for further assessment and intervention in cases of potential HDFN.
16
Question
Why is it crucial to detect FMH in pregnancy?
Answer
Detecting FMH is crucial because it helps in managing potential HDFN, allowing for timely interventions to reduce risks for the fetus or newborn.
17
Question
How does the presence of anti-D antibodies affect future pregnancies?
Answer
The presence of anti-D antibodies in a mother can lead to increased risks in future pregnancies, as prior sensitization may cause the mother's immune system to attack subsequent Rh-positive fetuses, leading to more severe forms of HDFN.
18
Question
What are the implications of maternal blood group in ABO HDFN?
Answer
If the mother is blood group O, she may develop antibodies against A or B antigens present on the fetal RBCs from the father, potentially leading to ABO incompatibility and mild HDFN.
19
Question
What are the possible outcomes of untreated severe HDFN?
Answer
Untreated severe HDFN can result in serious complications for the infant, such as severe anemia, jaundice, kernicterus (bilirubin encephalopathy), and even death.
20
Question
What is kernicterus and why is it a concern in HDFN?
Answer
Kernicterus is a condition resulting from high levels of bilirubin in the blood that affect the brain. It can lead to irreversible neurological damage, making it a significant concern in cases of severe HDFN.
21
Question
What is DAT in the context of blood tests?
Answer
DAT stands for Direct Antiglobulin Test, which detects the presence of antibodies on the surface of red blood cells in the baby's blood.
22
Question
What is the timing for performing a DAT test after delivery?
Answer
The DAT test should be performed within 72 hours of delivery.
23
Question
What does a negative result indicate in rosette testing?
Answer
A negative result in rosette testing indicates no significant fetal-maternal hemorrhage (FMH).
24
Question
What does a positive result indicate in rosette testing?
Answer
A positive result in rosette testing suggests that fetal cells are present in the maternal blood, potentially indicating fetal-maternal hemorrhage.
25
Question
What are the factors contributing to false positive and false negative FMH testing results?
Answer
False positives can occur if the mother is weak D. False negatives can occur if the baby is weak D.
26
Question
What is the KB test used for?
Answer
The KB test, also known as the Kleihauer-Betke acid elution test, is used to quantify fetal hemorrhage by measuring the percentage of fetal hemoglobin in maternal blood.
27
Question
Explain the principle of the acid elution test in detecting fetal blood.
Answer
The principle of the Kleihauer-Betke test relies on the resistance of fetal hemoglobin to acid, allowing fetal cells to be distinguished from maternal cells after exposure to an acidic environment.
28
Question
What dosage of RhIG (RhoGam) is typically administered?
Answer
One vial of RhIG (RhoGam) contains 300 micrograms and is sufficient to suppress a fetal bleed of up to 15 ml of PRBC (packed red blood cells).
29
Question
How is fetal hemorrhage calculated?
Answer
Fetal hemorrhage is calculated using the formula: (Fetal cells X maternal blood volume) / Total cells counted.
30
Question
If 6 fetal cells are counted in a maternal blood volume of 5000 ml with a total cell count of 2000, what is the fetal hemorrhage in ml?
Answer
Fetal hemorrhage = (6 x 5000) / 2000 = 15 ml.